

Special Issue

The Role of Molecular Hydrogen in Mitigating Oxidative Stress and Radiation Damage: Mechanistic Insights, Biological Effects, and Therapeutic Applications

Message from the Guest Editor

Molecular hydrogen (H₂) has emerged as a promising antioxidant and radioprotector with diverse therapeutic potential for mitigating oxidative stress and radiation-induced damage. This Special Issue aims to gather contributions that explore the latest insights into the mechanisms through which H₂ exerts its protective effects across various biological contexts, including neuroprotection, cancer therapy, radiation protection, and disease management. A particular emphasis will be placed on H₂'s ability to selectively scavenge reactive oxygen species (ROS), such as hydroxyl radicals (•OH) and peroxynitrite (ONOO[−]). The biological effects of H₂, including its potential to cross the blood–brain barrier and mitigate radiation-induced injury, will be thoroughly examined. In addition, the therapeutic applications of hydrogen-rich water, hydrogen inhalation, and intravenous H₂ as delivery methods will be discussed. This Special Issue will also explore the integration of molecular hydrogen into clinical practices, particularly in radiotherapy, where it holds promise for enhancing treatment outcomes.

Guest Editor

Prof. Dr. Jean Paul Jay-Gerin

Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

Deadline for manuscript submissions

30 June 2026



Radiation

an Open Access Journal
by MDPI

Indexed in Scopus



mdpi.com/si/250297

Radiation
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
radiation@mdpi.com

[mdpi.com/journal/
radiation](https://mdpi.com/journal/radiation)





Radiation

an Open Access Journal
by MDPI

Indexed in Scopus



[mdpi.com/journal/
radiation](https://mdpi.com/journal/radiation)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Gabriele Multhoff

Central Institute for Translational Cancer Research (TranslaTUM),
Klinikum rechts der Isar der Technischen Universität München, 81675
Munich, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.5 days after submission; acceptance to publication is undertaken in 5.1 days (median values for papers published in this journal in the first half of 2025).